Cancer represents a key challenge in medical science, manifesting as a disease where the immune system fails to recognize and eliminate tumor cells. The phenomenon of immune evasion by cancer cells ...
The only potentially curative options for gastric cancer involve endoscopic or surgical resection, with adjunctive systemic ...
Ipsen (IPSEY) stock rises after the FDA offered Breakthrough Therapy Designation for its antibody therapy IPN60340 in acute myeloid leukemia. Read more here.
Gastrointestinal (GI) cancers represent a complex interplay of genetic mutations, epigenetic alterations, and environmental factors. The initiation and progression of these cancers are influenced by ...
Revolution Medicines shows RAS drug optimism with phase 3 catalysts, early-stage valuation, buyout chatter, and competition ...
Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...
Zoldonrasib is an innovative tri-complex inhibitor that binds to cyclophilin A, creating a complex that selectively recognizes and inhibits the active, oncogenic RAS G12D (ON) mutant. Revolution ...
JSKN003 received breakthrough therapy designation for treating platinum-resistant ovarian, peritoneal, and fallopian tube cancers with HER2 expression. Clinical trials showed a 63% objective response ...
New from @hopkinskimmel: Researchers developed a TRBC2-targeting antibody–drug conjugate that selectively kills T-cell cancers while sparing healthy T cells in mice and lab models. The work expands a ...
T-DXd plus pertuzumab significantly improves progression-free survival in HER2-positive breast cancer, establishing a new first-line standard-of-care. Enfortumab vedotin and pembrolizumab surpass ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback